Tilray Brands stays a Buy as international medical cannabis revenue jumps 34% and U.S. rescheduling is proceeding. Click for why I remain bullish on TLRY stock.
Bringing you TOP Pot Stocks!
Tilray Brands stays a Buy as international medical cannabis revenue jumps 34% and U.S. rescheduling is proceeding. Click for why I remain bullish on TLRY stock.
Copyright © 2026 Cannabis Stocks News